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ABSTRACT
Here we examined the role of cellular vitamin C in
genotoxicity of carcinogenic chromium(VI) that
requires reduction to induce DNA damage. In the
presence of ascorbate (Asc), low 0.2–2 mM doses
of Cr(VI) caused 10–15 times more chromosomal
breakage in primary human bronchial epithelial cells
or lung fibroblasts. DNA double-strand breaks (DSB)
were preferentially generated in G2 phase as detected
by colocalization of gH2AX and 53BP1 foci in cyclin
B1-expressing cells. Asc dramatically increased the
formation of centromere-negative micronuclei, dem-
onstrating that induced DSB were inefficiently repai-
red. DSB in G2 cells were caused by aberrant
mismatch repair of Cr damage in replicated DNA, as
DNA polymerase inhibitor aphidicolin and silencing
of MSH2 or MLH1 by shRNA suppressed induction
of gH2AX and micronuclei. Cr(VI) was also up to
10 times more mutagenic in cells containing Asc.
Increasing Asc concentrations generated progres-
sively more mutations and DSB, revealing the geno-
toxic potential of otherwise nontoxic Cr(VI) doses.
Asc amplified genotoxicity of Cr(VI) by altering the
spectrum of DNA damage, as total Cr-DNA binding
was unchanged and post-Cr loading of Asc exhibited
no effects. Collectively, these studies demonstrated
that Asc-dependent metabolism is the main source of
genotoxic and mutagenic damage in Cr(VI)-exposed
cells.
INTRODUCTION
Occupational exposure to chromium(VI) has long been recog-
nized as a carcinogenic factor for the lung and other respira-
tory tissues (1,2). Approximately 360000 workers in the US
and several million worldwide are currently exposed to
Cr(VI) in the workplace. Frequent environmental contamina-
tion with this metal has raised signiﬁcant health concerns for
several non-industrial populations, particularly for those with
drinking water contamination or residing in close proximity
to large sites of chromate disposal (3,4). However, it has
also been argued that detoxiﬁcation processes should limit
cancer risk to the cases of massive occupational exposures
(5). Carcinogenic potential of Cr(VI) is supported by its abil-
ity to cause DNA damage and mutations, although its muta-
genicity has been found to be modest and typically detected
at very toxic doses (6). Recent epidemiological and risk
assessment studies conducted by the EPA have found
 25% lifetime risk of dying of lung cancer under the current
permissible exposure limit (PEL) (7,8). These ﬁndings served
as the basis for the OSHA decision in early 2006 to lower the
PEL for Cr(VI) by 10-fold (9). Even under the new standard,
a lifetime exposure was estimated to cause 10–45 additional
lung cancers per 1000 workers. This strikingly high cancer
risk for Cr(VI) exposures experienced by hundreds of thou-
sands of people requires a much better understanding of the
mechanisms of high Cr(VI) genotoxicity and adequate
approaches to assess it. Weak mutagenicity and the need
for relatively high doses for the induction of other genotoxic
responses were clearly inconsistent with the very strong
carcinogenic potential of Cr(VI).
Cr(VI) is a pro-carcinogen that generates DNA damaging
species via its reductive activation in cells by ascorbate
(Asc) and small thiols, such as cysteine and glutathione
(10). While the ﬁnal product of all reduction reactions is
always Cr(III), there are very important differences in reduc-
tion rates and the nature of intermediate products. Reduction
of Cr(VI) by thiols is relatively slow and produces transient
Cr(V) and Cr(IV) species, whereas reaction with the two-
electron donor Asc is fast and generates Cr(IV) as the main
intermediate (10,11). Metabolism of Cr(VI) by Asc and thiols
also yields different spectra of ternary Cr-DNA adducts (10).
The formation of Cr(V) intermediates have been frequently
considered an important indicator of the genotoxic conseq-
uences due to its ability to catalyze Fenton-like redox reac-
tions (12) and, in some ligand environments, to cause direct
DNA oxidation (13,14). However, there has been some tech-
nical bias for studies with Cr(V) because, unlike Cr(IV),
several relatively stable Cr(V) complexes could be synthe-
sized allowing examination of their genotoxic and chemical
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Cr(VI) in tissues (15) and does not directly generate Cr(V)
at physiological conditions (16,17), then one would predict
that only a rapid inﬂow of massive Cr(VI) doses resulting
in a severe drop in Asc levels could cause signiﬁcant Cr(V)
production and DNA damage. The causes for increased
Cr(V) formation under these conditions would include a
shift to thiol-dependent metabolism and increased stability
of Cr(IV) intermediates that can generate Cr(V) via secon-
dary reactions (10). However, the hypothesis on the overrid-
ing importance of Cr(V) is not supported by studies on the
formation of mutagenic damage in vitro (18) and the fact
that Cr(VI) is a weak mutagen in mammalian cells (6) that
rely on thiols to reduce Cr(VI) due to scarcity of cellular
Asc in the standard tissue cultures (10,19).
In this work, we examined the importance of cellular Asc
in the manifestation of the genotoxic abilities of Cr(VI). We
found that metabolism of Cr(VI) by cellular Asc caused dra-
matic increases in the formation of chromosomal damage and
mutations at the endogenous Hprt gene. Mechanistically,
increased DNA breakage was associated with abnormal pro-
cessing of Cr-DNA damage by the mismatch repair (MMR)
machinery of cells entering G2 phase.
MATERIALS AND METHODS
Cells and exposures
Primary human lung IMR90 ﬁbroblasts were obtained from
ATCC and typically used at passage 6–9. Primary human
bronchial epithelial (HBE) cells were purchased from Clonet-
ics and used at passage 4–6. All treatments with potassium
chromate (CrVI) were performed in serum-free media for
3 h. HBE cells were treated with Cr(VI) in RPMI1640 med-
ium supplemented with growth factors. Loading with Asc
was done by incubating cells for 90 min with dehydro-
ascorbic acid (DHA) in either Krebs-HEPES buffer supple-
mented with 0.5 mM glucose (IMR90, V79 and CHO cells)
or standard basal epithelial growth medium (HBE cells).
The following DHA concentrations were used: 5 mM for
IMR90; 50, 200 and 500 mM for HBE; 0.5, 1 and 2 mM
for V79; and 2 mM for CHO cells. In experiments with
arrested S-phase progression, 1 mM aphidicolin was added
15 min before Cr(VI) and was present during Cr exposure
and post-exposure incubations. Control cells were incubated
with equivalent concentrations of DMSO.
Asc measurements
Cellular Asc was measured by a modiﬁed HPLC procedure
based on the detection of a speciﬁc conjugate with 1,2-
diamino-4,5-dimethoxybenzene dihydrochloride (DDB) (19).
Cells were collected by trypsinization and washed three times
in cold PBS (1100 g for 5 min at 4 C). Cell pellets were
resuspended in 50 ml of ice-cold deionized H2O followed
by the addition of 50 ml of 100 mM methanesulfonic acid
containing 10 mM diethylenetriaminepentaacetic acid. Cells
were lysed by two cycles of freezing ( 80 C) and thawing
(37 C). Asc-containing supernatants were obtained after
centrifugation at 12000 g for 10 min at 4 C. Aliquots of
each sample (typically 10 ml) were mixed with 90 mlo fa
dye solution containing 0.2 units/ml Asc oxidase, 50 mM
sodium acetate (pH 6.2), and 0.5 mM DDB and incubated
for 4 h at room temperature in dark. Chromatographic separa-
tion was performed on Beckman Coulter Ultrasphere column
(ODS 5 mm, 4.6 mm · 250 mm) employing isocratic elution
with 75% 50 mM phosphoric acid (pH 2.0) and 25% aceto-
nitrile for 20 min. DHA-DDB conjugate was detected by its
characteristic ﬂuorescence (458 nm emission and 371 nm
excitation). HPLC analyses were performed with a Shimadzu
LC-10ADvp liquid chromatograph, equipped with a SIL-
10ADvp autosampler and an RF-10AxL ﬂuorescence detec-
tor. The detection limit for cellular Asc was 0.1 mM.
Chromium analyses
All Cr measurements were performed using graphite furnace
atomic absorption spectroscopy employing Zeeman back-
ground correction (Perkin-Elmer GF-AAS, model 41002L).
Instrumentation settings were as described previously (19).
Cellular Cr content was measured using nitric acid-prepared
extracts (20). For quantitation of Cr-DNA adducts, DNA
was isolated by a phenol-chloroform procedure omitting
EDTA (19). The detection limit was 0.4 pmol chromium or
1 Cr adduct per 10000 nt.
Microscopy
Cells were grown on Superfrost Plus slides, loaded with Asc,
exposed to Cr(VI) for 3 h and returned to complete medium.
Bromodeoxyuridine (BrdU) labeling was performed by
incubation with 10 mM of a cell proliferation labeling reagent
(Amersham) for 15 min in the dark prior to Cr exposure. At
the indicated times, cells were washed twice with PBS, ﬁxed
with 2% paraformaldehyde in PBS for 15 min and permeabi-
lized with 1% Triton X-100 for 15 min at room temperature.
For micronuclei scoring, slides were blocked for 1 h in 5%
goat serum at room temperature. Slides were then incubated
with anti-centromere CREST antibody (Antibodies, Inc.) at
1:200 dilution for 2 h at 37 C in a humidiﬁed chamber
followed by incubation with the secondary Alexa-Fluor
488-conjugated anti-human IgM antibody for 1 h. Nuclei
were counterstained with 40-60diamidino-2-phenylindole
(DAPI) and mounted with Vectasheild hard set mounting
medium (Vector Laboratories). Micronuclei were scored
from ﬂuorescence images recorded using a Nikon Eclipse
E800 digital microscope. At least 500 cells were analyzed
for each slide. For all other immunostainings, slides were
incubated with 2% FBS for 30 min at 37 C in a humidiﬁed
chamber. Double labeling was performed by simultaneous
incubation of primary antibodies for gH2AX at 1:150
(Upstate), anti-53BP1 at 1:200 (Santa Cruz), anti-BrdU at
1:100 (PharMingen), or anti-cyclin B1 at 1:200 (Santa
Cruz) dilutions for 2 h at 37 C in a humidiﬁed chamber.
Slides were washed three times with PBS for 5 min followed
by incubation with Alexa-Fluor 488-conjugated anti-mouse
IgG and Alexa-Fluor 594 or 564-conjugated anti-rabbit IgG
secondary antibodies (Molecular Probes) for 1 h at room tem-
perature. All antibodies were diluted in 2% bovine serum
albumin (BSA), with the exception of anti-BrdU staining
solution, which additionally contained 1 mM MgCl2 and
125 U/ml Benzonase nuclease (Novagen). Slides were
washed four times with PBS for 5 min and mounted with
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(Vector Laboratories). Fluorescence images were recorded
with a Zeiss Axiovert 100 confocal microscope and analyzed
by Phoenix and Metamorph software. Experiments were
repeated three to four times with at least 100 cells analyzed
on each slide. Slides were always coded and scored in a
blind manner.
Stable small interfering RNA knockdowns
Stable downregulation of MLH1 or MSH2 was achieved by
infections with a pSUPER-RETRO retroviral vector encoding
a hairpin forming small interfering RNA (siRNA). For cons-
truction, the pSUPER-RETRO plasmid was linearized with
HindIII and BglII to allow for insertion of the annealed
oligonucleotides directed towards the mRNA of interest.
MLH1 oligos were 50 gatccccggttcactactagtaaactttcaaga-
gaagtttactagtagtgaacctttttggaaa and 50 agcttttccaaaaaggttcac-
tactagtaaacttctcttgaaagtttactagtagtgaaccggg [design based on
Ref. (21)].
MSH2 oligos were 50 gatccccgagtgttgtgcttagtaaattcaaga-
gatttactaagcacaacactctttttggaaa and 50 agcttttccaaaaagagtgttg-
tgcttagtaaatctcttgaatttactaagcacaacactcggg.
Oligonucleotides targeting luciferase were used as a control:
50 gatccccgcgaccaacgccttgattgttcaagagacaatcaaggcgttggtc-
gctttttggaaa and 50 agcttttccaaaaagcgaccaacgccttgattgtctctt-
gaacaatcaaggcgttggtcgcggg. The pSUPER-RETRO vectors
were transfected into 293 cells with plasmids encoding viral
packaging proteins (22) using Plus reagent and Lipofec-
tamine (Invitrogen) according to the manufacturer’s instruc-
tions. Two days post-transfection, medium containing virus
particles was added to IMR90 cells and infections were
allowed to proceed for 24 h. Vector-expressing cells were
selected seven days post infection in the presence of 1.5
mg/ml of puromycin.
Western blotting
Protein extracts were prepared using a lysis buffer freshly
supplemented with protease and phosphatase inhibitors
[50 mM Tris (pH 8.0), 250 mM NaCl, 1% NP-40, 0.1%
SDS, 5 mM EDTA, 2 mM Na3VO4,1 0m MN a 2P2O7,
10 mM NaF, 10 mg/mL aprotinin, 10 mg/mL leupeptin,
0.5 mg/mL pepstatin, and 1 mM PMSF]. Cells were incubated
on ice for 10 min and then cell debris was spun down at
10000 g for 10 min. Proteins were separated by SDS–
PAGE and electrotransferred to ImmunoBlot PVDF mem-
brane (BioRad). Anti-MLH1 and anti-MSH2 (PharMingen)
primary antibodies were used. Protein bands were visualized
using horseradish peroxidase-conjugated secondary anti-
bodies (Upstate) and enhanced chemiluminescence kit
(Amersham).
Mutagenesis
V79 and CHO cells were routinely maintained in DMEM-
10%FBS and MEM-10%FBS media, respectively. Standard
media for both cell lines were supplemented with HAT
mixture (Invitrogen) for 7–9 days prior to seeding for Cr
exposures. Cells were seeded (0.5 · 10
6 cells) on 100 mm
dishes and allowed to attach overnight. Cells were then
loaded with Asc, exposed to Cr(VI) for 3 h, returned to com-
plete medium, and cultured for 7 days to allow expression of
the Hprt /  phenotype. Cells were reseeded in medium con-
taining 40 mM 6-thioguanine (6-TG) at a density of 0.5 · 10
6
cells per 100 mm dish. The plating efﬁciency (clonal sur-
vival) in the nonselective medium was also determined.
Ten to fourteen days after seeding, colonies were stained
with Giemsa solution and counted. Mutation frequency was
calculated by dividing the number of 6-TG resistant colonies
per 10
6 clonable cells.
RESULTS
Asc is a potent activator of DNA double-strand
breaking and clastogenic activities of Cr(VI)
We have previously noted that several transformed human
cells had very low or undetectable cellular Asc (19). Even
when freshly fed cells initially contained detectable amounts
of Asc (20–50 mM), it was lost during the next 1–2 days in
culture (23). To test whether primary human cells are also
Asc-deﬁcient, we measured Asc concentrations in IMR90
lung ﬁbroblasts using a highly sensitive HPLC assay (19).
We found that one day after seeding, IMR90 cells contained
barely detectable amounts of Asc (2.8 ± 1.1 mM, n ¼ 4)
(Figure 1A). To restore normal levels of Asc, we incubated
cells with DHA, which rapidly enters cells and is then
reduced to Asc (24). Loading of cells with Asc directly is
very inefﬁcient (19,25) and is usually associated with oxida-
tive stress and toxic effects caused by extracellular reactions
(25). Incubation of IMR90 ﬁbroblasts with 5 mM DHA cre-
ated 1 ± 0.2 mM (n ¼ 4) intracellular Asc, which was com-
parable to Asc levels in freshly puriﬁed human lymphocytes
(Figure 1A).
The effect of cellular Asc on the genotoxic potential of
Cr(VI) was ﬁrst examined by scoring cells containing foci
of Ser-139 phosphorylated H2AX (gH2AX), which are speci-
ﬁc quantitative markers of DNA double-strand breaks (DSB)
(26,27). We found that preloading with Asc greatly increased
the ability of low doses of Cr(VI) to cause gH2AX foci in
IMR90 cells (Figure 1C). In the linear response range (0–
2 mM Cr), Asc increased the yield of gH2AX-containing
cells by 5-fold. Enhanced formation of DNA breaks in Asc-
containing cells was observed at multiple time points after Cr
exposure although it appeared to be more pronounced at
earlier times (Figure 1D). Irrespective of their Asc status,
the majority of cells with gH2AX foci stained for G2 phase
marker cyclin B1 (Figure 1B). The percentage of gH2AX+
cells expressing cyclin B1 in Asc-containing samples was
75.6, 76.5, 73.6 and 92.7 for 1, 3, 6 and 12 h after exposure
to 3 mM Cr(VI). The corresponding values for Asc-free cells
were 46.7, 68.4, 71.4 and 77.1%. An apparent decrease in
the relative yield of gH2AX+ cells at the high Cr dose
(Figure 1C) therefore probably reﬂected limited amounts of
G2 cells (typically 14–16% for IMR90). Staining for
gH2AX was not due to apoptotic DNA breaks because addi-
tion of the validated antiapoptotic dose of 50 mM Z-VAD-
FMK pancaspase inhibitor had no effect on the percentage
of Asc-containing cells with gH2AX foci (10.1 ± 1.2%
without and 10.2 ± 0.8% with Z-VAD for 2 mMC ra t6h
post-exposure; 14.2 ± 2.8% versus 13 ± 2.9% at 18 h).
To assess the levels of unrepaired DSB, we scored the
number of cells with micronuclei (28,29). Treatment with
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of micronuclei in Asc-loaded IMR90 cells whereas the
responses in Asc-deﬁcient cells were very small if any
(Figure 1E). On average, cellular Asc increased the yield of
micronuclei by 6.6-fold. Cr-induced micronuclei resulted
primarily from clastogenic events (chromosomal breaks)
because the majority of them were negative for staining
with anti-kinetochore CREST antibody (Figure 1E). One
reason for the highly elevated genotoxicity of Cr(VI) by cel-
lular Asc could have been enhanced Cr(VI) accumulation
and/or increased formation of Cr-DNA adducts. However,
we found that both Cr(VI) uptake and Cr-DNA binding
were in fact lower in Asc-loaded IMR90 cells by 2.1- and
2.3-fold, respectively (Figure 1F and G). We traced the
diminished Cr loading to the leakage of cellular Asc,
which led to the reduction of Cr(VI) outside the cell. After
normalization for the differences in uptake, the presence
of 1 mM Asc in IMR90 cells increased the levels of
Cr(VI)-induced DSB by 10.5-fold and the number of
micronuclei by 13.9-fold.
Figure 1. Increased genotoxicity of Cr(VI) in IMR90 cells containing Asc. (A) Representative HPLC profiles for Asc determinations in protein-normalized
extracts. (B) Confocal images of IMR90 cells immunostained for gH2AX, cyclin B1 and counterstained with DAPI. Control or 1 mM Asc-loaded cells were
treated with 2 mM Cr(VI) for 3 h and fixed 6 h later. (C) Preloading with 1 mM Asc increased the number of cells with gH2AX foci at different Cr doses and (D)
times after exposure. Dose-dependence was measured at 6 h post-exposure and time-dependence was determined with 3 mM Cr(VI). Cells with four or more foci
were defined as positive. Results are means ± SD for at least four slides with >100 cells scored per slide. Data in panel D are after subtraction of background
values in Cr-untreated samples (1.9 ± 0.7 and 1.6 ± 0.6 for Asc  and Asc+ samples, respectively). (E) Elevated frequency of micronuclei in cells loaded with
1 mM Asc prior to Cr(VI) exposure. Micronuclei were scored 48 h after Cr exposure. Closed symbols—total micronuclei, open symbols—CREST-negative
micronuclei. Data are means ± SD for four slides with >500 cells counted per slide. (F) Cells preloaded with 1 mM Asc had lower uptake of Cr(VI) and (G) lower
Cr-DNA binding. Results are means ± SD for 3–5 independent samples.
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related foci formation in primary HBE cells. These cells
were grown in synthetic medium without serum and had
no detectable Asc. Loading of HBE cells with Asc was highly
efﬁcient even using low concentrations of DHA (Figure 2A).
The presence of 0–1.7 mM cellular Asc had only a minor
effect on Cr(VI) accumulation (Figure 2B), which permitted
easier testing of Asc dose-dependence. We found that even
the subphysiological concentration of 0.6 mM Asc caused a
major increase in formation of gH2AX foci in HBE cells at
Figure 2. Asc caused concentration-dependent increases in DSB foci and micronuclei in primary HBE cells. (A) Accumulation of Asc by HBE cells. Data are
means ± SD for six independent samples. (B) Cr(VI) uptake by HBE cells containing different Asc concentrations. Data are means ± SD for four independent
samples. (C) Confocal images of cells immunostained for gH2AX, 53BP1 and counterstained with DAPI. Control and preloaded with 1.7 mM Asc-cells were
treated with 2 mM Cr(VI) for 3 h and fixed 6 h later. (D) Preloading with Asc increased the number of cells containing foci of gH2AX and (E) 53BP1. Slides were
fixed for immunostaining at 6 h after Cr treatment. Cells containing >4 foci were scored as positive. Data are means ± SD for four to eight slides with >100 cells
counted per slide. (F) Asc-promoted gH2AX foci were preferentially formed in cells expressing a G2 phase-specific marker cyclin B1. Cells lacking or containing
1.7 mM Asc were treated with 2 mM (left panel) or 5 mM Cr(VI) (right panel). H2AX—percentage of gH2AX+ cells, dual—percentage of cells that are positive
for both gH2AX and cyclin B1. Data are means ± SD for four slides with >100 cells/slide. (G) Physiological but not low levels of Asc caused delayed induction
of gH2AX after exposure to subtoxic 0.5 mM Cr(VI). Foci were scored at 9 and 18 h after Cr treatment of cells containing 0, 0.6 or 1.7 mM Asc. Results are
means ± SD for four slides with >450 cells counted. Data are after subtraction of background values in Cr-untreated samples (9 h: 0.7 ± 0.5, 1.6 ± 1.2 and 1.4 ±
1.2%; 18 h: 0.4 ± 0.8, 0.2 ± 0.4 and 0.5 ± 0.5% for 0, 0.6 and 1.7 mM Asc samples, respectively). (H) Percentage of G2 cells detected by positive immunostaining
for cyclin B1. Cells with (1.7 mM) and without Asc were treated with 2 mM Cr(VI) and fixed for immunofluorescence at 3 and 12 h post-exposure. Data are
means ± SD for three slides with >100 cells/slide counted. (I) Preloading with Asc (1.7 mM) increased the induction of micronuclei by Cr(VI). Results are
means ± SD for eight slides with >1000 cells/slide counted. Closed symbols—total micronuclei, open symbols—CREST-negative micronuclei.
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1.7 and 3 mM Asc were even more susceptible to DSB induc-
tion. Analysis of another quantitative marker of DSB, 53BP1
foci (30), also revealed highly elevated levels of DSB in Asc+
cells treated with Cr (Figure 2E). 53BP1 is recruited to DSB
prior to Ser-139 phosphorylation of H2AX (31) and indepen-
dently of any other DSB-responsive proteins (32). The mag-
nitude of increase in gH2AX and 53BP1 foci by 3 mM Asc
was particularly striking because these cells had signiﬁcantly
lower uptake of Cr(VI) (Figure 2B). For 2 mM Cr(VI) expo-
sures, cells without Asc had no changes in gH2AX foci
whereas preloading with 1.7 and 3 mM Asc led to 7.5
and 20-fold increases above untreated controls, respectively.
All gH2AX+ cells invariably contained 53BP1 foci and
the majority of gH2AX and 53BP1 foci colocalized
(Figure 2C). Approximately 3% of control cells contained
53BP1 foci but no gH2AX foci and this fraction of cells
remained constant irrespective of any Asc or Cr manipula-
tions. In contrast to the frequency of foci+ cells, Asc had
no impact on the number of DSB foci per foci-positive cell.
For example, 5 mM Cr(VI) treatments induced 11.3 versus
12.2 gH2AX foci/cell and 15.6 versus 16.3 53BP1 foci/cell
for no Asc and 1.7 mM Asc-containing HBE cells, respec-
tively (6 h post-Cr analyses). Examination of other post-
exposure times and lower Cr doses also failed to detect any
signiﬁcant differences in the number of gH2AX foci per posi-
tive cell between Asc+ and Asc  samples (e.g for 2 mM Cr:
11.7 versus 10.3 at 3 h and 12.8 versus 11.9 foci/cell at 12 h
for 1.7 mM Asc-loaded and no Asc samples, respectively).
These results suggested that the main effect of Asc was mani-
fested in the increased fraction of cells susceptible for DSB
induction, not in the increased amount of DNA damage.
This interpretation is also consistent with the observed
independence of Cr-DNA binding on the presence of Asc
(Figure 2B).
Time-course studies showed that Asc-promoted DSB did
not appear until 3 h post-Cr exposure and either leveled
off (5 mM Cr) or continued to increase at 6 h (2 mM Cr)
(Figure 2F). Data collected at 6 h post-Cr revealed an
upward trend but not a major increase in DSB foci for
cells with 1.7 versus 0.6 mM Asc (Figure 2D and E),
which could have been a result of a particular combination
of Cr doses and timing. To further investigate potential dif-
ferences between normal and subphysiological Asc levels,
we studied DSB formation at longer post-exposure times
using a very low dose of 0.5 mM Cr(VI). We found that
the presence of physiological 1.7 mM Asc did cause
increased processing of Cr-DNA damage into DSB, which
became clearly evident at 18 h after exposure (Figure 2G).
We found that 80–95% of DSB were induced in G2 phase
as detected by dual staining of gH2AX and cyclin B1
(Figure 2F). However, not all G2 cells were susceptible to
DSB induction, as the number of cyclin B1+ cells exceeded
the number of gH2AX+ cells, particularly for lower Cr
doses and early times (compare Figure 2H versus
Figure 2F, left panel). While Asc alone had no effect on
the size of the G2 population, its presence induced
detectable increases in the percentage of G2 cells after Cr
exposure (Figure 2H). This modest alteration in cell cycle
distribution probably resulted from a delayed progression
of DSB-containing G2 cells into mitosis.
To test whether DSB generated by low levels of Cr damage
hadclastogenicconsequences,we scoredthenumberofmicro-
nuclei in control and 1.7 mM Asc-preloaded cells. We found
that cellular Asc strongly promoted the formation of micro-
nuclei following Cr(VI) treatments (Figure 2I). At 0.5 mM
Cr(VI), the number of micronuclei in Asc-loaded cells was
13-times above untreated controls whereas Asc-free cells
showed only a marginal response. About 95% of Cr-induced
micronuclei lacked kinetochores (CREST-negative), indica-
ting clastogenic mechanism of their formation.
Asc is a potent enhancer of Cr(VI) mutagenicity
Next, we examined the effects of cellular Asc on Cr(VI)
mutagenicity at the Hprt locus in two standard test lines,
CHO and V79 (33). Control experiments have shown that pre-
loading of CHO cells with 1.4 mM Asc led to 2.6-times lower
Cr(VI) accumulation (Figure 3A) and decreased Cr-DNA
binding (Figure 3B). The diminished number of Cr-DNA
adducts in Asc+ cells was a direct result of lower Cr accumu-
lation, as evidenced by essentially identical plots of Cr-DNA
adducts versus intracellular Cr concentrations (Figure 3C). To
correct for the observed uptake differences, we therefore ana-
lyzed mutagenic responses as a function of cellular Cr doses
(Figure 3D). We found that 0–220 mM cellular Cr(VI) doses
were non-mutagenic in control CHO cells containing 15 mM
Asc. In contrast, preloading of these cells with 1.4 mM Asc
caused a strong, linear increase in the frequency of Hprt
mutants, which reached a 19.2-fold increase over background
for the highest Cr dose. The presence of Asc also increased
clonogenic lethality of Cr in CHO cells (Figure 3E), although
the differences in toxicity were signiﬁcantly less pronounced
than for the mutagenic responses. Cr(VI) mutagenicity was
also enhanced by Asc in a concentration-dependent manner
at the Hprt locus of V79 cells (Figure 3G). While treatment
of control V79 cells with 10 mM Cr(VI) produced only a mar-
ginal increase in the number of Hprt mutants, the same dose
of Cr caused progressively greater mutagenic responses in
cells preloaded with increasing Asc concentrations, yielding
almost 10 times more mutants for 3.4 mM Asc-containing
cells relative to control cells. Uptake studies showed that
loading of V79 cells with Asc had either no effect or
only a modest, 25% decrease for 3.4 mM Asc samples
(Figure 3F). Lack of mutagenic responses in Asc-deﬁcient
CHO cells treated with mildly toxic doses of Cr(VI) did not
mean that Cr(VI) was completely non-mutagenic in the
absence of vitamin C. We found that when the cellular
dose of Cr was raised to 0.45 mM, this induced a signiﬁcant,
3.8-fold increase (SD ¼ 1.0, n ¼ 4) in the number of Hprt
mutants in Asc-deﬁcient CHO populations.
Potentiating effects of Asc result from its effects on
metabolism of Cr(VI)
Increased genetic damage due to cellular Asc can result from
the changes in the types of DNA lesions and/or altered
cellular responses to the same Cr-DNA damage. To evaluate
these possibilities, we examined genotoxic and mutagenic
responses in cells loaded with Asc 1 h after Cr treatments.
This time interval is sufﬁcient for the completion of Cr(VI)
reduction in Asc-free cells (34,35). We found that the
post-Cr delivery of Asc had no detectable effect on the
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of gH2AX-containing HBE cells or Hprt mutagenesis in
CHO cells (Figure 4A–C). These results clearly demonstrate
that Asc does not change biological responses to Cr-DNA
damage that is already formed. Therefore, the potentiating
abilities of Asc must stem from the altered metabolism of
Cr(VI) and resulting changes in the spectrum of DNA lesions.
Suppression of clastogenic responses by downregulation
of MSH2 and MLH1 MMR proteins
Here we investigated whether ampliﬁcation of clastogenic
damage by Asc was a direct result of the formation of highly
toxic DNA lesions or if it was caused by stronger cellular
responses to Asc-mediated Cr-DNA damage. We focused
our attention on the potential role of MMR proteins as they
have recently been found to enhance genotoxic responses
in human colon cancer cells treated with Cr(VI) under stan-
dard tissue culture conditions (36). To create deﬁciency in
primary MMR human cells, we infected IMR90 ﬁbroblasts
with retroviral constructs expressing short hairpin (sh)RNA
targeting MSH2 and MLH1. Both MSH2 and MLH1 are
essential MMR proteins and the loss of either protein causes
complete MMR deﬁciency (37,38). The shRNA-expressing
vectors were very effective and decreased amounts of MLH1
and MSH2 proteins to barely detectable levels (Figure 5A).
Depletion of either MLH1 or MSH2 dramatically suppressed
the frequency of micronuclei induced by Cr(VI) in both
Asc+ (Figure 5B) and Asc  cells (Figure 5C). For low
Cr-DNA damage induced by 0.5 mM Cr(VI), loss of MMR
proteins led to a complete abrogation of clastogenic events
detected by the micronucleus assay. To explore a potential
link between MMR-induced micronuclei and DSB, we also
analyzed formation of gH2AX in the same Cr dose range
(0–1 mM Cr) as a function of MLH1 and MSH2 status. We
Figure 3. Cellular Asc strongly increases mutagenicity of Cr(VI). (A)C r
uptake and (B) Cr-DNA binding in control (15 mM Asc) and Asc-preloaded
(1.4 mM) CHO cells. Means ± SD for 3–6 independent samples. (C) Yield of
Cr-DNA adducts in CHO cells as a function of intracellular Cr dose. (D)
Frequency of Hprt mutants in control (15 mM Asc) and Asc-preloaded
(1.4 mM) CHO cells. Cells were treated with 0–40 mM Cr(VI). Mutation
frequencies are means±SD for four independent populations. (E) Clonogenic
survival of control and 1.4 mM Asc-containing CHO cells. Data are means ±
SD from two clonogenic assays with triplicate dishes. (F) Cr uptake (means ±
SD, n ¼ 4) and (G) Cr-induced Hprt mutagenesis in V79 cells containing
different concentrations of Asc. Cells were exposed to 10 mM Cr(VI). Data
are means ± SD for 4–8 independently treated populations. Background
frequencies were 3.6 · 10
 5 for control (0.8 mM Asc), 3.4 · 10
 5 for 1.3 mM,
3.9 · 10
 5 for 2.2 mM and 2.8 · 10
 5 for 3.4 mM Asc-containing cells.
Figure 4. Post-exposure loading of Asc had no effect on genotoxicity and
mutagenicity of Cr(VI). Asc was loaded into cells 1 h after Cr(VI) exposure.
(A) Formation of micronuclei in IMR90 cells. (B) Frequency of gH2AX foci-
containing HBE cells and (C) Hprt mutagenesis in CHO cells. CHO cells
were loaded with 1.4 mM Asc either before (Asc!Cr) or 1 h after (Cr!Asc)
exposure to 10 mM Cr(VI). Results are means ± SD.
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strongly decreased the number of gH2AX+ cells in both
Asc+ (Figure 5D) and Asc  populations (Figure 5E). Sup-
pression of MMR essentially eliminated the formation of
DSB in G2 cells, as evidenced by almost complete absence
of gH2AX/cyclin B1 double positive cells (Figure 5F and
G). Overall, these results strongly link MMR to the induction
of DSB and micronuclei in Cr-treated cells.
Formation of gH2AX in G2 phase requires passage of
cells through S-phase
The observed G2-selectivity in DSB induction was clearly not
a result of some intrinsic susceptibility of all G2 cells since
the percentage of gH2AX+ cells was signiﬁcantly lower
than the total number of G2 cells, particularly at early post-
exposure times. We therefore sought to explore a possibility
that susceptible G2 populations are formed by Cr-damaged
cells that progressed through S-phase. To test this hypothesis,
we scored the number of gH2AX+ cells in the presence
and absence of DNA polymerase inhibitor aphidicolin
(Figure 6A–D). We found that aphidicolin strongly decreased
the total number of gH2AX+ cells in both HBE (Figure 6A
and B) and IMR90 (Figure 6C and D) cells irrespective of
their Asc status. The inhibitory effect of aphidicolin on
DSB induction was even more striking for G2 cells, which
led to the complete absence of gH2AX/cyclin B1 dual posi-
tive cells. It should be noted that the presence of aphidicolin
diminished G2 populations by  2–2.5-fold (Figure 6E and F),
which still left  6–8% of cells that entered G2 phase before
addition of aphidicolin and Cr.
Since entry of Cr-damaged cells from S to G2 phase had
such a profound effect on the induction of gH2AX, we also
examined whether the differences in genotoxic responses
between Asc+ and Asc  cells were associated with poten-
tially varying rates of S to G2 progression. To explore this
possibility, we pulse-labeled replicating cells with BrdU
prior to Cr treatments and then analyzed the appearance of
BrdU-tagged DNA in G2 phase by co-staining with anti-
BrdU and anti-cyclin B1 antibodies. These experiments
found that Asc had no effect on the rate of S to G2 progres-
sion at 1–6 h post-Cr (Figure 6G and H), a time interval when
Asc+ cells always had dramatically higher levels of gH2AX
(Figure 6, compare A versus B, C versus D). In accordance
with the S-dependent sensitization of G2 cells, the overall
number of BrdU/B1 dual positive Asc+ cells roughly corre-
sponded to the number of gH2AX/B1 dual positive Asc+
cells (Figure 6, panels G and D).
DISCUSSION
Mechanism of Asc-promoted chromate genotoxicity
Our studies demonstrated that cellular Asc acted as a potent
ampliﬁer of clastogenic and mutagenic activities of carcino-
genic Cr(VI). Potentiating effects of Asc were observed
when it was present during Cr(VI) metabolism (preloading
experiments) but no effects on clastogenic or mutagenic
responses were detected when Asc was introduced following
exposure and reduction of Cr(VI). Therefore, the targets of
Asc were Cr(VI) metabolism and resulting DNA damage
rather than cellular damage response mechanisms. Asc-
promoted clastogenesis was not the result of the formation
of some intrinsically more genotoxic damage, because the
induction of DSB foci and micronuclei were almost
completely suppressed by stable knockdowns of MSH2 or
MLH1 MMR proteins. Thus, unrepaired chromosomal breaks
were apparently caused by aberrant processing of Asc-
promoted Cr-DNA damage by MMR proteins. Considering
that Asc is the fastest biological reducer of Cr(VI) (10),
Figure 5. Suppression of gH2AX and micronuclei formation by stable
downregulation of MLH1 and MSH2 proteins. (A) Western blots for MSH2
and MLH1 in IMR90 cells expressing targeting (MLH1, MSH2) and non-
specific (Luc) shRNA. Frequency of micronuclei in IMR90 cells (B)
preloaded with 1 mM Asc (C) in Asc-deficient cells. Data are means ± SD for
four slides with >1000 cells counted per slide. Induction of gH2AX by Cr(VI)
in cells (D) containing 1 mM Asc and (E) lacking Asc. Slides were fixed for
immunofluorescence at 18 h post-Cr. Data are means ± SD for four slides
with >200 cells/slide counted. Frequency of gH2AX/cyclin B1 double
positive cells in (F) Asc-loaded and (G) Asc-deficient samples. Experimental
conditions were as in panels (D) and (E).
472 Nucleic Acids Research, 2007, Vol. 35, No. 2one of the direct consequences of Asc’s presence is a more
rapid reduction of Cr(VI) to stable Cr(III). This by itself
may not be very important since Cr-DNA binding in cells
was independent of the Asc status. A truly unique aspect of
Cr(VI) metabolism by Asc is the formation of highly muta-
genic Asc-Cr-DNA crosslinks (19,39). Thus, elevated muta-
genic activity of Cr(VI) in CHO and V79 cells was
probably a result of the formation of this premutagenic lesion.
It is possible that other forms of DNA damage were also
induced by Asc loading (40), although shuttle-vector experi-
ments did not ﬁnd evidence for a signiﬁcant role of oxidative
damage in mutagenic responses generated by Asc-Cr(VI)
reactions in vitro (18,39). A consideration of the complete
set of experimental ﬁndings leads us to propose a model of
Asc-enhanced genotoxicity involving the formation of pre-
mutagenic Asc-Cr-DNA crosslinks (Figure 7). In this
model, premutagenic Asc-Cr-DNA adducts generate a high
frequency of base mispairs during DNA replication and the
resulting compound lesions (Cr-DNA adducts containing
mismatches) are recognized by MMR. This then leads to
the aberrant processing and production of DSB in G2 cells.
Progression of G2 cells with unrepaired DSB into mitosis
would generate clastogenic events that were detected as
kinetochore-negative micronuclei in our experiments. The
same mechanism for the induction of DSB and micronuclei
should also operate for Asc  cells with the exception that
thiol-stimulated DNA damage is poorly mutagenic, which
consequently should cause only weak base mispairing
and mild activation of MMR. It is possible that S-phase
creates favorable conditions for the direct detection of Asc-
Cr-DNA adducts by MMR proteins although in the cases of
other DNA adducts, compound lesions were always detected
with much higher speciﬁcity (41,42).
Cr is not unique in its ability to activate genotoxicity in a
MMR-dependent manner. It has been known for quite some
time that toxicity of SN1 methylating agents (MNNG, MNU
and their clinical analogues) forming O
6-methylguanine
requires the presence of MMR proteins (43,44). Other exam-
ples of genotoxicants with MMR-mediated toxic responses
include cisplatin and thiopurines (45,46). As with Cr, DNA
Figure 7. A model of Asc-promoted genotoxicity and mutagenicity of
carcinogenic chromium(VI).
Figure 6. DNA polymerase inhibitor aphidicolin abolished induction of DSB
in G2 cells. All experiments were conducted with 3 mM Cr(VI) exposures for
3 h. Aphidicolin (1 mM) was added 15 min before Cr and was present during
and after Cr exposures. Cells were fixed for immunostaining at 1, 3 and 6 h
post-Cr treatments. Data are means ± SD for four slides with >100 cells/slide
counted. (A) Effect of aphidicolin on frequency of total gH2AX+ (H2AX)
and gH2AX/cyclin B1 dual positive (dual) HBE cells lacking Asc, or (B)
preloaded with 1.7 mM Asc. Panels A and B have the same legend. (C) Effect
of aphidicolin on frequency of total gH2AX+ (H2AX) and gH2AX/cyclin B1
dual positive (dual) IMR90 cells lacking Asc, or (D) preloaded with 1 mM
Asc. Panels C and D have the same legend. In untreated controls, frequency
of gH2AX+ cells varied from 0.3 to 0.9% for IMR90 cells, and from 0.3 to
0.6% for HBE cells. (E) Percentage of cyclin B1-positive HBE and (F)
IMR90 cells in the presence or absence of aphidicolin. Closed symbols—no
aphidicolin ( Aph), open symbols—1 mM aphidicolin (+Aph); squares +Asc,
diamonds  Asc. (G) Assessment of S to G2 progression in Cr-treated or (H)
untreated IMR90 cells containing or lacking Asc. Cells were labeled with
10 mM BrdU for 15 min prior to 3 mM Cr and fixed for immunostaining at 1, 3
and 6 h post-Cr. Data are means±SD for three slides with >100 cells counted
per slide.
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in cells treated with MNNG and 6-thioguanine. However,
the induction of DNA breaks does not follow the same
pattern for any two types of DNA damaging agents. For 6-
thioguanine, MMR generated only single-strand breaks
(SSB) even after two rounds of cell cycle (47) while process-
ing of O
6methyl-G produced SSB after the ﬁrst S-phase and
then DSB in the second S-phase (48). The formation of DSB
in the second S-phase was proposed to result from the
unavoidable termination of replication at the sites of SSB.
While the formation of persistent SSB from repetitive cycles
of MMR across highly mutagenic DNA lesions (futile repair
cycling) would be expected, the induction of DSB in Cr-
treated cells after the ﬁrst round of replication is unprece-
dented and must originate from a different mechanism than
breakage generation for other genotoxicants. Sensitivity of
SSB repair deﬁcient XRCC1 /  and proﬁcient XRCC1+
cells to low-moderate amounts of Cr-DNA damage has been
found to be very similar (20), indicating that SSB are not
important toxic lesions and consequently, that Cr-induced
DSB did not result from the SSB to DSB conversion
sequence. We favor a possibility that DSB in Cr-treated
cells are caused by collapsed replication forks. In this sce-
nario, assembly of MMR complexes at the sites of Cr-DNA
damage or Cr-induced mismatches stalls replication forks
that remain intact as long as cells remain in S-phase. Transi-
tion of cells from S to G2 inactivates fork viability mecha-
nisms resulting in collapsed forks, which are known to
result in the generation of DSB (49,50).
Implications for chromium carcinogenesis
We have recently proposed that occupational Cr carcino-
genesis may involve selection of Cr-resistant, MMR-deﬁcient
cells (36,51). This selection model was based on a MMR-
dependent mechanism of apoptosis in Cr(VI)-treated cells
(36) and is further supported by a high frequency of
microsatellite instability (52) and the loss of MLH1 expres-
sion in lung cancers among chromate workers (53). The
selection process is expected to operate most efﬁciently at
toxic, repetitive exposures. Suppression of DNA DSB and
micronuclei formation by subtoxic exposures in cells with
stable knockdowns of MLH1 or MSH2 indicates that MMR
can also promote carcinogenesis by environmental doses of
Cr via potentiation of chromosomal instability. Taken toge-
ther, these results suggest that MMR plays a major role in
the cellular responses to Cr over a broad range of doses
and therefore, it may represent an important factor in the
individual susceptibility to genetic damage in Cr-exposed
populations.
A key mechanistic difference in Cr(VI) reduction by Asc
relative to other reducers is the absence of Cr(V) intermediate
under physiologically relevant conditions (16,17). The forma-
tion of Cr(V) was only detectable when Cr(VI) was present in
equimolar or excess amounts over Asc concentrations, experi-
mental conditions that would approximate rare massive
human exposures to Cr(VI). Although it has been previously
suggested that Cr(V) could be an important DNA-reactive
intermediate, highly elevated genotoxic and mutagenic res-
ponses in Asc-containing cells treated with low to moderate
doses of Cr strongly argue against any major biological role
of Cr(V). In fact, further channeling of Cr(VI) into Cr(V)-
skipping metabolism by increasing cellular levels of Asc
caused progressively more genetic damage. The same conclu-
sion was also drawn from in vitro studies on the formation of
mutagenic DNA damage in Cr(VI)-Asc reactions (18,39).
These mechanistic considerations predict that DNA damage
induction should be a linear or near linear function of cellular
Cr doses, which is what we found for Cr-DNA binding and
biological indices of genotoxicity, such as DSB, micronuclei
and mutagenesis. Thus, our studies did not ﬁnd any support
for the notion that there is a safe range of Cr doses, resulting
from the suppression of Cr(V) formation by Asc. Overall, our
results raise a possibility that consumption of large amounts
of vitamin C accompanied by its high tissue accumulation
could in fact exacerbate genetic damage of Cr(VI) exposures.
This scenario would resemble a situation with another metal-
caused disease, hemochromatosis, the dietary management of
which includes a recommendation of avoiding excess vitamin
C to decrease redox cycling of iron (54).
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